ArticleAnalytical chemistry2025
Diagnosis On-Demand: Field Evaluation of Microfluidic Paper Device for the Detection of Asymptomatic Malaria.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A paper-based immunoassay with signal amplification for the sensitive detection of nucleocapsid protein toward the diagnosis of long COVID.The Analyst · 2026Article
- Application of multi-channel magnetic particle immunofluorescent disc microfluidic chip for combined detection of antibodies against six common infectious diseases including visceral leishmaniasis in pastoral areas.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We report a proof-of-concept surveillance strategy that combines simplicity with modest cost to achieve high analytical performance for the detection of asymptomatic malaria infection. We developed a microfluidic paper-based analytical device (μPAD) that automates immunoassay using 30 μL of whole blood. A novel dendrimer-based signal transduction method was introduced to amplify the mass spectrometry (MS) signal. Our ability to detect an immunoassay signal with MS was achieved using cleavable ionic probes that were attached to monoclonal antibodies via dendrimer bioconjugation. The limit of detection of this MS-based immunoassay was determined to be 4.5 pM in serum for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.